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Background: Cancer patients and survivors regularly feel anxious about cancer recurrence or death, even after the
conclusion of medical treatment, and they are often highly physiologically and psychologically stressed. Massage
therapy is one of the most widely used complementary and alternative therapies used in the hope of alleviating
such stress and physical and psychological complaints and to improve health-related quality of life. This
randomized phase III, two-armed, parallel group, clinical trial was designed after obtaining positive findings in a
preliminary study. The primary objective is to verify the effects of continuous Japanese massage therapy, referred to
as Anma therapy, for cancer survivors. The secondary objective is to confirm the immediate effects of a single Anma
massage session for cancer survivors.
Methods/Design: Sixty cancer survivors older than 20 years of age who have had histologically confirmed uterine
cervical, endometrial, ovarian, fallopian tube or peritoneal cancer in the past, but with no recurrence for more than
3 years since receiving standard medical treatment, are being recruited by gynecologists in medical facilities. In the
coordinating office, they are randomly allocated to two groups (n = 30 each): an Anma massage group receiving a
40-min Anma massage session once weekly over a 2-month intervention period (total of eight Anma massage
sessions) and a control group being followed by medical doctors and receiving no Anma massage sessions. The
primary end point is the severity of physical subjective symptoms that cancer survivors report in daily life, assessed
using a Visual Analogue Scale. Secondary end points are urine and saliva analyses, psychological condition and
health-related quality-of-life scores as determined on the basis of a self-report questionnaire.
Discussion: Using the evidence-based findings of this trial, medical professionals should be able to explain the
benefits conferred by Anma massage to cancer survivors and provide higher-quality information to better inform
patients regarding their decisions about whether to receive such therapy.
Trial registration: This trial is registered with the UMIN Clinical Trials Registry as UMIN000009097.
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Since 1981, cancer has been the leading cause of death
in the Japanese population. In 2011, there were 357,305
cancer deaths (28.5% of all deaths), 210,000 of which
were men and 140,000 were women, and the number of
such deaths is increasing because of the aging of the
population [1]. In addition, the incidence of cancer is in-
creasing, exceeding 700,000 (410,000 men and 290,000
women) according to the latest data [2]. It is estimated
that the yearly average number of cancer deaths and
cancer incidence for the period 2025 to 2029 in Japan
will be approximately 230,000 men and 160,000 women
and 530,000 men and 390,000 women, respectively [3].
Both the number of cancer deaths [4] and cancer inci-
dence [3] for men are expected to slow after 2015,
whereas for women these figures, especially regarding
the incidence of cancers of the oral cavity and pharynx,
kidney and urinary tract, uterus, lung, pancreas and cer-
vix are expected to continue increasing at the present
rate [4]. It is also known that early detection and pro-
gressive treatment options have improved the prognosis
of cancer patients and increased the number of cancer
survivors in Japan [5], and accordingly interest has been
shifting from radical treatment options toward ensuring
a better quality of life (QoL) for patients to cope with
the disease [6].
Cancer patients and survivors regularly feel anxious
about cancer recurrence or death, even after the conclu-
sion of medical treatment, and it is known that they are
highly stressed, both physiologically and psychologically
[7-9]. Although 65% of men living with cancer are older
than 65 years of age, 68.2%, 72.8%, 68.7% and 70.6% of
women with breast, uterine, thyroid and ovarian cancer,
respectively, are younger than 65 years old [5]. Because
the time women live with cancer is thought to be longer
than that of men, it may be especially necessary to pro-
vide enhanced physical and mental care to female cancer
survivors.
Numerous studies on massage for patients with cancer
have been conducted in Western countries in recent
years. The findings of many of these studies imply that
massage therapy may help to improve the physical and
psychological symptoms of cancer patients [10-13], and
patients receiving massage therapy in a pilot study
reported improvements in stress and QoL [14]. Massage
is, in fact, one of the most commonly used complemen-
tary and alternative therapies for cancer [15].
Japanese massage therapy, known as Anma therapy
(hereinafter Anma massage therapy), is one of the most
popular complementary and alternative therapies in
Japan. It has long been used with the aim of improving
or alleviating physical and psychological symptoms.
With high expectations for Anma massage therapy, we
previously conducted a preliminary study to assesswhether Anma massage therapy confers physical and
psychological benefits in five cancer survivors who had
undergone surgery for uterine cervical or endometrial
cancer (stages Ia1 to IIa) [16]. All participants received
Anma massage therapy consisting of eight 40-min Anma
massage sessions over 4 wk. In regard to immediate
changes in variables after a single Anma massage
session, physical subjective symptoms assessed using a
Visual Analogue Scale (VAS) were significantly im-
proved, state anxiety score and salivary cortisol were
lowered and secretory immunoglobulin A (s-IgA) was
significantly increased. In addition, after seven con-
tinuous Anma massage sessions, VAS score, anxiety
score and depression score were all lowered. On the
basis of these preliminary findings, we designed the
present randomized trial to verify the effects of Anma
massage therapy compared with no Anma massage
therapy. The primary objective of the trial is to verify
the effects of continuous Anma massage therapy for
cancer survivors. The secondary objective of the trial
is to confirm the immediate physical and emotional
effects of a single Anma massage session.
Methods and design
Study design and setting
This study is a randomized, two-armed, parallel group
clinical trial. The coordinating office is at Tsukuba
University of Technology, Japan. Gynecologists in other
medical facilities introduce the coordinating office to
patients who meet the eligibility criteria and confirm they
do not meet any exclusion criteria.
When patients show interest in trial participation, the
gynecologists send an introduction form to the coordin-
ating office by facsimile. The coordinating office calls
the introduced patient to decide the date on which to
meet to explain the trial, and the patient visits the office
to be given information verbally on the trial and reads
the written trial description. After the meeting, the pa-
tient submits the consent form by hand, facsimile or
mail upon deciding to register for the trial. Accrual
started on 12 October 2012, and the term for patient
registration for the trial is within 2 years from this date.
Sixty participants are planned to be recruited.
Ethical consideration and study registration
The study protocol was designed in accordance with the
World Medical Association’s Helsinki Declaration [17]
and the Ethics Guidelines for Clinical Research of the
Ministry of Health, Labor, and Welfare of Japan [18].
This trial was approved by the Medical Ethics Committee
of Tsukuba University of Technology, Japan, on 27
September 2012 (Approval No. 5) and was registered
with the UMIN Clinical Trials Registry as application
UMIN000009097 on 12 October 2012.
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The inclusion criteria are (1) histologically confirmed
uterine cervical, endometrial, ovarian, fallopian tube or
peritoneal cancer in the past; (2) no recurrence of such
cancer for more than 3 years since receiving standard
medical treatment; (3) older than 20 years of age at the
date of registration for the trial; (4) patient’s doctor
deems the patient to be eligible for the trial; and (5)
receipt of written informed consent from the patient to
participate in the trial. The exclusion criteria are (1) active
infections; (2) serious concurrent disease of the heart, liver
or kidney, etc.; and (3) severe mental disorders.
Randomization
After finishing registration, the patients are allocated by
block randomization by the coordinating office to con-
tinuous Anma massage therapy or no Anma massage
therapy, except for a single Anma massage therapy inter-
vention at the end of the trial period (Figure 1). Alloca-
tion adjustment factors are not set in the trial because ofrecruit pa
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inform
registra
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Figure 1 Trial Flow Diagram.insufficient evidence at present regarding which factors
affect the effectiveness of Anma massage therapy.
Protocol treatment
Interventions
Anma massage therapy group This group receives
treatment by continuous Anma massage therapy
according to the trial protocol. The protocol treatment
is completed when the patient finishes receiving the final
40-min Anma massage session of a total of eight ses-
sions given once weekly over a 2-month intervention
period. Anma massage therapy techniques consist of
standard versions of Japanese massage, mainly kneading
with lesser amounts of stroking and pressing. Anma
massage is performed through clothing, with the inten-
sity of stimulation applied being within each person’s
range of comfort. On a massage table, a full-body Anma
massage excluding the face, head and abdomen is
performed following the procedure described in detail in
our previous studies [16,19,20], with a focus on therticipants
and exclusion criteria
rdinating office
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tion
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ical symptoms. A therapist provides all massage sessions
to avoid differences in technical capabilities. This therap-
ist has a national massage practitioner license and over
20 years of experience and was the therapist involved in
providing Anma massage treatment sessions in our
previous studies [16,19,20].
No Anma massage therapy group This control group
is followed by their medical doctors as usual and do not
receive the continuous Anma massage sessions. Patients
visit the coordinating office and have a 40-min relaxing
chat with a massage therapist while lying on a massage
table, but without receiving a massage. Two months
later they return to the office to receive a single 40-min
Anma massage session.
End points
The primary end point is the severity of subjective phys-
ical complaints that cancer survivors report in daily life
as measured using a VAS. To assess the severity of sub-
jective physical complaints, a sheet of paper (width
100 mm × height 40 mm) is given to the participant,
and it is explained that the left edge of the paper repre-
sents no complaint and the right edge the most serious
complaint that the participant can imagine. The partici-
pant records the seriousness of the degree of the subject-
ive complaint at that time as a check mark on the paper.
The length from the left edge to the check mark is
measured and considered the VAS score.
The secondary end points of the study are as follows.
(1) The score on the Profile of Mood State–Brief
Japanese Version (POMS) questionnaire is used to assess
immediate psychological effects. (2) The score on the
Hospital Anxiety Depression Scale–Japanese version
(HADS), a 14-item scale developed to assess anxiety and
depression for particular cancer patients. (3) The score on
the European Organization for Research and Treatment of
Cancer QLQ-C30–Japanese version (EORTC QLQ-C30)
scale, which was developed to assess health-related QoL,
particularly in cancer patients. The subscales are global
health status, functional scales (physical functioning, role
functioning, emotional functioning, cognitive functioning
and social functioning) and symptom scales (fatigue,
nausea and vomiting, pain, dyspnea, insomnia, appetite
loss, constipation, diarrhea and financial difficulties).
(4) The score on the Measure of Adjustment to Cancer–
Japanese version (MAC) questionnaire, because some
studies [21,22] have reported a correlation between
adjustment of cancer, QoL and mental health. Be-
cause some communication between the patient and
massage therapist is commonly built into massage
sessions, psychological adjustment to cancer (coping
style to cancer) may change through such communicationduring continuous Anma massage therapy. (5) The
level of 8-hydroxydeoxyguanosine and catecholamine
(noradrenaline, adrenaline and dopamine) in urine is mea-
sured. (6) Levels of cortisol, chromogranin A and s-IgA in
saliva are measured.
Data collection
Data collection is performed on three occasions in the
Anma massage group: before and after the first Anma
massage session (measurements A and B) and before the
last (eighth) Anma massage session (measurement C)
(Figure 1). Data collection is conducted on four occa-
sions in the control group: before and after the relaxing
chat session (measurements D and E) and before and
after the single Anma massage session (measurements
F and G) at 2 months (Figure 1).
To assess the effects of continuous Anma massage ses-
sions, changes in all end points between measurements
A and C are compared with those between measure-
ments D and F.
In addition, to confirm immediate changes following a
single Anma massage session, which is the secondary
objective of the trial, changes in VAS score, POMS
score, and levels of 8-hydroxydeoxyguanosine, catechol-
amine (noradrenaline, adrenaline and dopamine), salivary
cortisol, chromogranin A, and s-IgA between measure-
ments A and B are compared with those between mea-
surements D and E. Such changes between measurement
F and measurement G are also considered as additional
evidence to confirm the immediate effects of a single
Anma massage session.
Sample size determination
In our preliminary study [16], the mean VAS score be-
fore the first Anma massage session in cancer survivors
was 40.4, which was reduced to 19.6 before the last
(eighth) Anma massage session. The mean VAS score
difference during 2 months was −20.8 (standard devi-
ation (SD) 19.6). We assume for the no Anma massage
group that the mean difference will be unchanged (that
is, zero) and that its SD will be the same as that of the
Anma massage group (that is, 19.6). To test these differ-
ences between the two groups, with a 5% type I error
rate and 90% power, a sample size of 14 patients per
group is required. For sensitivity analysis, we also con-
sider the following situations: the mean VAS score differ-
ences in the no–Anma massage group will be −5, –7.5
and −10, in which case sample sizes of 24, 33 and 49 pa-
tients per group, respectively, are required for 90% power,
and 18, 25 and 37 patients per group, respectively, are re-
quired for 80% power. Therefore, the planned sample size
will be 30 participants per group (60 participants in total).
A sample size of 30 patients per group will also account
for possible data loss or dropouts.
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Analysis of pretreatment characteristics and efficacy ana-
lysis will be performed according to the modified
intention-to-treat principle and will include all partici-
pants who receive at least one Anma massage session in
the Anma massage therapy group and one relaxing chat
in the no–Anma massage group. If necessary, we might
also perform sensitivity analyses, adding all eligible
patients who are introduced by medical doctors to the
coordinating office but are not registered.
The primary end point is VAS score improvement over
the 2-month study period. For primary analysis, we will
use the analysis of covariance to compare the mean
changes in VAS score over the 2 months between the
Anma massage group and the no–Anma massage group,
adjusting for the baseline VAS score and age. If we find
other significant prognostic factors, we will use them as
additional adjusting factors. We will also use a two-
sample t-test with Satterthwaite’s approximation to com-
pare the mean changes. We will also test the mean
changes in VAS score for each group using a paired
t-test. For these mean VAS score changes and their
differences, we will also calculate two-sided 95% con-
fidence intervals (CIs) to evaluate the clinical effects.
For the secondary end points, we will not consider
multiplicity issues. In all analyses, categorical variables
will be described in terms of frequency and percentage.
The distributions of continuous variables will be de-
scribed using means, SDs, medians, and minimum and
maximum values. A two-sample t-test or paired t-test
will be used to detect differences in continuous variables.
Pearson’s χ2 test with continuity correction will be used
to test differences in categorical variables. If these data
are found not to be normally distributed, we will use in
their place the Wilcoxon signed-rank test or the Mann-
Whitney U test, respectively. All reported P values will
be two-sided. All significance levels will be set at 0.05,
and reported CIs will be 95%. In principle, we will use
the available-case analysis for missing outcomes. SAS
statistical software (version 9.3 or later; SAS Institute,
Cary, NC, USA) will be used for all analyses.
Discussion
This trial is considered to correspond to a phase III
study because of the preliminary study undertaking and
because the randomized confirmatory trial has signifi-
cance for the primary end point set at 5%, addressing
the effects of longer-term intervention. This trial will
employ adequate methods to reduce bias, such as
randomization, a large subject population and analysis
according to the intent-to-treat principle.
Regardless of whether the results of this trial are posi-
tive or negative, in the current situation, where benefits
conferred to the body and mind by Anma massagetherapy for cancer survivors are controversial, the find-
ings of this trial will help to provide an answer to this
controversy and will be reflected in the guidelines for
cancer care. At present, patients decide of their own will
whether they receive Anma massage therapy. Using the
evidence-based findings of this trial, medical profes-
sionals should be able to explain the benefits conferred
by Anma massage to cancer survivors and provide
higher-quality information to better inform patients in
their decisions about whether to receive such therapy.
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